Hims & Hers (Hims) Q2 Profit 2025

On Wednesday, February 12, 2025, on Wednesday, February 12, 2025, on Wednesday, February 12, 2025, on Wednesday, February 12, 2025.

Gabi Jones | Bloomberg | Gets the image

Shares His health and her On Monday after the Telehealth Company decreased by 9%, after Telehealth reported the results of the second quarter, which missed Wall Street’s expectations.

Here’s how the company made the estimates of the average analyst compiled by LSEG:

  • Profit per share: 17 cents, adjusted against 15 cents
  • Income: 544.8 million dollars against $ 552 million

Revenues in Hers & Hers increased by 73% in the second quarter of $ 315.6 million over the same period last year, according to the issue. HIMS & Hers reported a net profit of $ 42.5 million, or 17 cents per share, compared to $ 13.3 million, or 6 cents per share a year earlier.

In the third quarter, Hits & Hers said it reports from $ 570 to $ 590, and analysts expected $ 583 million. The company said its adjusted EBITDA will be between the range of $ 60 to $ 70 million. Analysts surveyed by Stretaccount expected $ 77.1 million.

In recent months, Hits & Hers have encountered GLP-1sWhat are the cheaper, unauthorized versions of the blockbuster’s diabetes and weight loss medication. Recurdened drugs can be massively produced if brand procedures are lying deficiencyBut the US Power Office and the US Medicines announced In February, the supply problems were solved.

Some television companies, including Hims & Hers, continue to offer complex medicines. For patients, it is legally accessed to personalized doses of sets in unique cases, such as if they are, such as allergies to the ingredient in the branded product. Its and her eat – Note Consumers can still access personalized doses through their site if clinically applicable.

In June, Hims & Hers shares collapsed by more than 30% after short -term cooperation since Novo nordisk It fell apart. The drug creator stated that he and her “did not adhere to the law that prohibits the mass sales of complex drugs” under “false appearance” of personalization.

Hits & Hers reported that in the second quarter, EBITDA had been adjusted at $ 82 million, compared to $ 39.3 million last year and above $ 73 million waiting for Stretaccount.

The Hims & Hers will take its quarterly call with investors at 5 pm.

Schedule iconSchedule icon

Hide the content

ITD -graph of his health.

-CNBC Annika Kim Constantino contributed to this report

Source link